Literature DB >> 7552725

The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase.

P J Loll1, D Picot, R M Garavito.   

Abstract

Aspirin exerts its anti-inflammatory effects through selective acetylation of serine 530 on prostaglandin H2 synthase (PGHS). Here we present the 3.4 A resolution X-ray crystal structure of PGHS isoform-1 inactivated by the potent aspirin analogue 2-bromoacetoxy-benzoic acid. Acetylation by this analogue abolishes cyclooxygenase activity by steric blockage of the active-site channel and not through a large conformational change. We observe two rotameric states of the acetyl-serine side chain which block the channel to different extents, a result which may explain the dissimilar effects of aspirin on the two PGHS isoforms. We also observe the product salicylic acid binding at a site consistent with its antagonistic effect on aspirin activity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7552725     DOI: 10.1038/nsb0895-637

Source DB:  PubMed          Journal:  Nat Struct Biol        ISSN: 1072-8368


  86 in total

1.  Substitution, insertion, deletion, suppression, and altered substrate specificity in functional protocatechuate 3,4-dioxygenases.

Authors:  D A D'Argenio; M W Vetting; D H Ohlendorf; L N Ornston
Journal:  J Bacteriol       Date:  1999-10       Impact factor: 3.490

2.  Automated docking and molecular dynamics simulations of nimesulide in the cyclooxygenase active site of human prostaglandin-endoperoxide synthase-2 (COX-2).

Authors:  R García-Nieto; C Pérez; F Gago
Journal:  J Comput Aided Mol Des       Date:  2000-02       Impact factor: 3.686

3.  Induction of an acetaminophen-sensitive cyclooxygenase with reduced sensitivity to nonsteroid antiinflammatory drugs.

Authors:  D L Simmons; R M Botting; P M Robertson; M L Madsen; J R Vane
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

4.  A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin.

Authors:  M Ouellet; D Riendeau; M D Percival
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

Review 5.  COX in a crystal ball: current status and future promise of prostaglandin research.

Authors:  G A FitzGerald; P Loll
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

Review 6.  Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  John W Eikelboom; Jack Hirsh; Frederick A Spencer; Trevor P Baglin; Jeffrey I Weitz
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 7.  Contemporary treatment of unstable angina and non-ST-segment-elevation myocardial infarction (part 2).

Authors:  Shehzad Sami; James T Willerson
Journal:  Tex Heart Inst J       Date:  2010

8.  Aspirin as a Potential Geroprotector: Experimental Data and Clinical Evidence.

Authors:  Oleh Lushchak; Veronika Piskovatska; Olha Strilbytska; Iryna Kindrat; Nadya Stefanyshyn; Alexander Koliada; Volodymyr Bubalo; Kenneth B Storey; Alexander Vaiserman
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 9.  Pharmacology of antiplatelet agents.

Authors:  Kiran Kalra; Christopher J Franzese; Martin G Gesheff; Eli I Lev; Shachi Pandya; Kevin P Bliden; Udaya S Tantry; Paul A Gurbel
Journal:  Curr Atheroscler Rep       Date:  2013-12       Impact factor: 5.113

Review 10.  Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk.

Authors:  Allison B Goldfine; Steven E Shoelson
Journal:  J Clin Invest       Date:  2017-01-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.